R&D Trends

Novartis in-licensing ECF843 for ophthalmic indications

Tuesday, April 11, 2017

Novartis announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed.

[Read More]

CSSi LifeSciences, the Prince William Science Accelerator partner

Friday, April 7, 2017

CSSi LifeSciences, a partner from discovery to commercialization for biologics and vaccines, is partnering with the Prince William Science Accelerator, a public-private, commercially available wet lab space in Northern Virginia. The partnership promotes the development of new businesses and the retention and expansion of existing businesses within the county’s growing and diverse life sciences community through CSSi LifeSciences’ technical assistance, regulatory, clinical and commercial assessment for all Prince William Science Accelerator tenants.

[Read More]

Y Combinator launches Science Exchange-powered marketplace for R&D

Wednesday, April 5, 2017

Science Exchange, a marketplace for outsourced R&D, has announced a strategic partnership with Y Combinator (YC). YC-backed companies will now have exclusive access to the Science Exchange-powered YC marketplace, where they can instantly order experimental services from a network of over 2,500 qualified scientific service providers, all with pre-established contracts that protect companies’ IP and confidentiality.

[Read More]

Janssen Pharmaceutical, Premier collaborate on atrial fibrillation study

Wednesday, April 5, 2017

Janssen Pharmaceuticals is collaborating with Premier on the first and largest study of its kind to address an unmet medical need for hospitalized patients with atrial fibrillation (AF) who are at risk for ischemic stroke. Named QUANTUM AF (Quantify Use of ANTicoagUlation to improve Management of AF), the study will evaluate the effect of a structured hospital quality improvement (QI) program on oral anticoagulant (OAC) use in these patients.

[Read More]